Sagimet Biosciences Inc.
Sagimet Biosciences Inc. (SGMT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
sgmt · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Sagimet Biosciences Inc.You SGMT | $218M | N/A | — | -$1.34 |
 Achieve Life Sciences, Inc. ACHV | $563M | N/A | — | -$1.25 |
 Arcturus Therapeutics Holdings Inc. ARCT | $209M | N/A | — | -$2.40 |
 Assembly Biosciences, Inc. ASMB | $375M | N/A | — | -$0.55 |
 Atea Pharmaceuticals, Inc. AVIR | $346M | N/A | — | -$1.94 |
 Foghorn Therapeutics Inc. FHTX | $225M | N/A | — | -$1.18 |
 Humacyte, Inc. HUMA | $244M | N/A | — | -$0.26 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Sagimet Biosciences Inc. (SGMT) measures how much investors pay for each dollar of the company's trailing earnings. SGMT's current PE ratio of N/A is calculated by dividing its stock price of $6.70 by its TTM earnings per share of -$1.34.
Frequently asked questions
SGMT pe ratio · 6 questionsSGMT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $6.70 and TTM EPS of -$1.34. Data sourced from Financial Modeling Prep via SGMT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Sagimet Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09